Insmed to Host R&D Day on September 30, 2020

Insmed, a biopharmaceutical company, will host a virtual R&D Day on September 30, 2020, from 10:00 a.m. to 12:30 p.m. ET.

Rhea-AI Summary

Insmed, a biopharmaceutical company, will host a virtual R&D Day on September 30, 2020, from 10:00 a.m. to 12:30 p.m. ET. The event will highlight updates on pipeline candidates, including treprostinil palmitil and brensocatib, as well as advancements for ARIKAYCE (amikacin liposome inhalation suspension). Dr. Ronald J. Oudiz will present during the event. The conference call will be accessible live and recorded for later viewing. Insmed focuses on serious and rare diseases with its innovative therapies.

Argus Session date unavailable

+5.60% session move Open Argus

Details

News Market Reaction – INSM

The recorded move for INSM in the trading session of this news was +5.60%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER, N.J., Sept. 16, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host an R&D Day on Wednesday, September 30, 2020. The event is scheduled to take place from 10:00 a.m. to 12:30 p.m. ET in a virtual format.

The agenda will include an overview of recent developments for the Company's pipeline candidates treprostinil palmitil and brensocatib, as well as label expansion efforts and global advancement updates for ARIKAYCE^® (amikacin liposome inhalation suspension).

The program will also feature a presentation by Ronald J. Oudiz, M.D., FACP, FACC, FCCP. Dr. Oudiz is a Professor of Medicine at the David Geffen School of Medicine at UCLA, the Interim Chief, Division of Cardiology, and a Director at the Liu Center for Pulmonary Hypertension Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

The call and accompanying slides will be webcast live on the company's website at https://investor.insmed.com/events. To listen to the conference call live, please dial (888) 317-6003 (domestic) or (412) 317-6061 (international) and reference conference ID number 0587949.

A replay of the conference call will be accessible approximately one hour after its completion through October 14, 2020 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing replay access code 10147009. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at https://investor.insmed.com/events.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product, ARIKAYCE^® (amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment of refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a chronic, debilitating condition that can cause severe and permanent lung damage. Insmed is also advancing brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in bronchiectasis and other inflammatory diseases, and treprostinil palmitil, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.

Contact:

Investors:
Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
insmed@argotpartners.com 

Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-rd-day-on-september-30-2020-301131791.html

SOURCE Insmed Incorporated

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date and time of Insmed's R&D Day 2020?

Insmed's R&D Day is scheduled for September 30, 2020, from 10:00 a.m. to 12:30 p.m. ET.

How can I listen to Insmed's R&D Day conference call?

You can listen to the conference call live by dialing (888) 317-6003 for domestic callers or (412) 317-6061 for international callers.

What will be discussed during Insmed's R&D Day?

The R&D Day will cover recent developments in pipeline candidates such as treprostinil palmitil and brensocatib, alongside updates on ARIKAYCE.

Who is presenting at Insmed's R&D Day?

Dr. Ronald J. Oudiz, a Professor of Medicine at UCLA, will present during Insmed's R&D Day.

How long will the replay of the conference call be available?

A replay of the conference call will be available until October 14, 2020.

What is the focus of Insmed as a biopharmaceutical company?

Insmed is focused on transforming the lives of patients with serious and rare diseases through innovative therapies.